|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.86/-3.48
|
企业价值
951.74M
|
资产负债 |
每股账面净值
7.25
|
现金流量 |
现金流量率
--
|
损益表 |
收益
1.58M
|
每股收益
0.08
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 20:20 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis. |